Raymond James Financial Inc. Invests $19 Million in Haemonetics Co. (NYSE:HAE)

Raymond James Financial Inc. acquired a new stake in shares of Haemonetics Co. (NYSE:HAE - Free Report) in the 4th quarter, according to its most recent 13F filing with the SEC. The fund acquired 243,364 shares of the medical instruments supplier's stock, valued at approximately $19,002,000. Raymond James Financial Inc. owned 0.48% of Haemonetics at the end of the most recent quarter.

Other institutional investors and hedge funds have also bought and sold shares of the company. Parkside Financial Bank & Trust lifted its stake in Haemonetics by 25.6% during the 4th quarter. Parkside Financial Bank & Trust now owns 1,176 shares of the medical instruments supplier's stock valued at $92,000 after acquiring an additional 240 shares during the period. KBC Group NV lifted its stake in Haemonetics by 54.6% during the 4th quarter. KBC Group NV now owns 2,016 shares of the medical instruments supplier's stock valued at $157,000 after acquiring an additional 712 shares during the period. iSAM Funds UK Ltd acquired a new stake in Haemonetics during the 3rd quarter valued at approximately $204,000. Empowered Funds LLC acquired a new position in shares of Haemonetics in the 4th quarter valued at $319,000. Finally, Captrust Financial Advisors lifted its stake in shares of Haemonetics by 30.1% in the 3rd quarter. Captrust Financial Advisors now owns 4,248 shares of the medical instruments supplier's stock valued at $341,000 after purchasing an additional 982 shares during the period. 99.67% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several equities analysts recently issued reports on HAE shares. JPMorgan Chase & Co. started coverage on shares of Haemonetics in a research note on Friday, December 6th. They issued an "overweight" rating and a $116.00 target price for the company. JMP Securities decreased their target price on shares of Haemonetics from $125.00 to $100.00 and set a "market outperform" rating for the company in a research note on Friday, February 7th. Raymond James reiterated a "strong-buy" rating and issued a $115.00 target price (down from $120.00) on shares of Haemonetics in a research note on Friday, February 7th. StockNews.com cut shares of Haemonetics from a "buy" rating to a "hold" rating in a research note on Saturday, February 15th. Finally, Bank of America cut shares of Haemonetics from a "neutral" rating to an "underperform" rating and decreased their target price for the company from $95.00 to $68.00 in a research note on Friday, February 7th. One research analyst has rated the stock with a sell rating, two have issued a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $101.22.

Remove Ads

Haemonetics Price Performance

NYSE:HAE traded down $0.95 during trading hours on Thursday, reaching $64.28. 611,753 shares of the company were exchanged, compared to its average volume of 648,785. The company has a current ratio of 3.97, a quick ratio of 2.55 and a debt-to-equity ratio of 1.35. The stock's 50-day moving average is $67.82 and its 200-day moving average is $75.19. The firm has a market cap of $3.23 billion, a PE ratio of 25.31, a price-to-earnings-growth ratio of 1.11 and a beta of 0.43. Haemonetics Co. has a twelve month low of $58.80 and a twelve month high of $97.97.

Haemonetics (NYSE:HAE - Get Free Report) last posted its quarterly earnings data on Thursday, February 6th. The medical instruments supplier reported $1.19 earnings per share for the quarter, missing analysts' consensus estimates of $1.20 by ($0.01). Haemonetics had a return on equity of 23.66% and a net margin of 9.47%. On average, sell-side analysts anticipate that Haemonetics Co. will post 4.55 earnings per share for the current fiscal year.

Haemonetics Company Profile

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.